Early cost-effectiveness analysis of risk-based selection strategies for adjuvant treatment in stage II colon cancer: the potential value of prognostic molecular markers

BACKGROUND: To explore the potential value of Consensus Molecular Subtypes (CMS) in stage II colon cancer (CC) treatment selection, we carried out an early cost-effectiveness assessment of a CMS-based strategy for adjuvant chemotherapy. METHODS: We used a Markov cohort model to evaluate three select...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Epidemiol Biomarkers Prev
Main Authors: Jongeneel, Gabrielle, Greuter, Marjolein J.E., Kunst, Natalia, van Erning, Felice N., Koopman, Miriam, Medema, Jan P., Vermeulen, Louis, Ijzermans, Jan N.M., Vink, Geraldine R., Punt, Cornelis J.A., Coupé, Veerle M.H.
Formato: Artigo
Idioma:Inglês
Publicado: 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611620/
https://ncbi.nlm.nih.gov/pubmed/34162659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-21-0078
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares